CVX Vaccine Codes
CDC Immunization & Vaccine Code Set
In 1999, the CDC published an implementation guide for messaging immunization histories. Two value sets were defined that allowed specification of the vaccine used at the vaccine administration level. The CVX code is a numeric string, which identifies the type of vaccine product used. The MVX code is an alphabetic string that identifies the manufacturer of that vaccine. Taken together, the immunization can be resolved to a trade name (the proprietary name of the product).
For example, a CVX code of 43 represents Hepatitis B, adult formulation. There are 2 manufacturers of this vaccine, GlaxoSmithKline (MVX = SKB) and Merck (MVX = MSD). An immunization using Recombivax, a Hepatitis B vaccine manufactured by Merck, would have a CVX of 43 and an MVX of MSD.
When these codes were developed, they were designed to accommodate reporting of vaccine histories when the manufacturer and trade name are not known. This is because a client often had a shot card listing the vaccinations received, but with only a date and vaccine group listed. If the manufacturer and formulation were not known, then the Hepatitis B vaccine administered would be coded with a CVX of 45 (Hepatitis B, not otherwise specified).
Other codes exist that are associated with the coding of a vaccine. These include: RxNorm, NDC, and CPT®. RxNorm, a standardized nomenclature for clinical drugs and drug delivery devices, is produced by the National Library of Medicine (NLM). In RxNorm, the name of a clinical drug combines its ingredients, strengths, and/or form.
Typically, there are a number of factors that determine which vaccine will have the same or a different CVX code:
- the formulation
- the concentration
- the manufacturing process (egg culture vs. cell culture)
- the route of administration
The CDC's National Center of Immunization and Respiratory Diseases (NCIRD) developed and maintains the CVX (vaccine administered) code set. CVX codes for inactive vaccines allow transmission of historical immunization records. When a MVX (manufacturer) code is paired with a CVX (vaccine administered) code, the specific trade named vaccine may be indicated.
Use ICD-10-CM code Z23 Encounter for immunization to. CPT® codes are specific to the type of vaccine.
MVX Codes - Manufacturers of Vaccines
The MVX is an alphabetic string, which represents the manufacturer of a vaccine. When MVX code is paired with a CVX (vaccine administered) code, the specific trade named vaccine may be indicated. The MVX code reflects the manufacturer of the specific instance of the vaccine. For example, Pfizer (MVX = PFR) acquired Wyeth (MVX = WAL). Prevnar is a vaccine that was manufactured by Wyeth. Immunizations of Prevnar that were manufactured by Wyeth continue to use the MVX of WAL. Prevnar that is now manufactured by Pfizer will have an MVX of PFR. Existing records will not be changed.
source: https://www.cdc.gov/vaccines/programs/iis/downloads/business-rules.pdf
143 | Adenovirus types 4 and 7 | Active |
54 | adenovirus, type 4 | Inactive |
55 | adenovirus, type 7 | Inactive |
82 | adenovirus, unspecified formulation | Inactive |
174 | cholera, live attenuated | Active |
173 | cholera, BivWC | Non-US |
172 | cholera, WC-rBS | Non-US |
26 | cholera, unspecified formulation | Inactive |
28 | DT (pediatric) | Active |
20 | DTaP | Active |
106 | DTaP, 5 pertussis antigens | Active |
146 | DTaP,IPV,Hib,HepB | Active |
110 | DTaP-Hep B-IPV | Active |
120 | DTaP-Hib-IPV | Active |
130 | DTaP-IPV | Active |
170 | DTAP/IPV/HIB - non-US | Non-US |
102 | DTP-Hib-Hep B | Non-US |
107 | DTaP, unspecified formulation | Inactive |
50 | DTaP-Hib | Inactive |
132 | DTaP-IPV-HIB-HEP B, historical | Inactive |
01 | DTP | Inactive |
22 | DTP-Hib | Inactive |
52 | Hep A, adult | Active |
83 | Hep A, ped/adol, 2 dose | Active |
104 | Hep A-Hep B | Active |
193 | Hep A-Hep B, pediatric/adolescent | Non-US |
84 | Hep A, ped/adol, 3 dose | Inactive |
31 | Hep A, pediatric, unspecified formulation | Inactive |
85 | Hep A, unspecified formulation | Inactive |
146 | DTaP,IPV,Hib,HepB | Active |
110 | DTaP-Hep B-IPV | Active |
104 | Hep A-Hep B | Active |
08 | Hep B, adolescent or pediatric | Active |
43 | Hep B, adult | Active |
44 | Hep B, dialysis | Active |
220 | HepB recombinant, 3-antigen, Al(OH)3 | Active |
189 | HepB-CpG | Active |
102 | DTP-Hib-Hep B | Non-US |
193 | Hep A-Hep B, pediatric/adolescent | Non-US |
132 | DTaP-IPV-HIB-HEP B, historical | Inactive |
42 | Hep B, adolescent/high risk infant | Inactive |
45 | Hep B, unspecified formulation | Inactive |
51 | Hib-Hep B | Inactive |
146 | DTaP,IPV,Hib,HepB | Active |
120 | DTaP-Hib-IPV | Active |
49 | Hib (PRP-OMP) | Active |
48 | Hib (PRP-T) | Active |
170 | DTAP/IPV/HIB - non-US | Non-US |
102 | DTP-Hib-Hep B | Non-US |
50 | DTaP-Hib | Inactive |
132 | DTaP-IPV-HIB-HEP B, historical | Inactive |
22 | DTP-Hib | Inactive |
47 | Hib (HbOC) | Inactive |
46 | Hib (PRP-D) | Inactive |
17 | Hib, unspecified formulation | Inactive |
51 | Hib-Hep B | Inactive |
148 | Meningococcal C/Y-HIB PRP | Inactive |
62 | HPV, quadrivalent | Active |
165 | HPV9 | Active |
118 | HPV, bivalent | Inactive |
137 | HPV, unspecified formulation | Inactive |
66 | Lyme disease | Inactive |
146 | DTaP,IPV,Hib,HepB | Active |
110 | DTaP-Hep B-IPV | Active |
120 | DTaP-Hib-IPV | Active |
130 | DTaP-IPV | Active |
10 | IPV | Active |
195 | DT, IPV adsorbed | Non-US |
170 | DTAP/IPV/HIB - non-US | Non-US |
132 | DTaP-IPV-HIB-HEP B, historical | Inactive |
02 | OPV | Inactive |
89 | polio, unspecified formulation | Inactive |
119 | rotavirus, monovalent | Active |
116 | rotavirus, pentavalent | Active |
74 | rotavirus, tetravalent | Inactive |
122 | rotavirus, unspecified formulation | Inactive |
25 | typhoid, oral | Active |
101 | typhoid, ViCPs | Active |
41 | typhoid, parenteral | Inactive |
53 | typhoid, parenteral, AKD (U.S. military) | Inactive |
91 | typhoid, unspecified formulation | Inactive |
81 | VEE, inactivated | Inactive |
80 | VEE, live | Inactive |
92 | VEE, unspecified formulation | Inactive |
121 | zoster live | Active |
187 | zoster recombinant | Active |
188 | zoster, unspecified formulation | Inactive |
current/active
Parent Company of MedImmune
210 | COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL | Active | AstraZeneca COVID-19 Vaccine (Non-US tradenames include VAXZEVRIA, COVISHIELD) |
manufacturer of national stockpile smallpox vaccine Jynneos
206 | Vaccinia, smallpox Mpox vaccine live, PF, SQ or ID injection | Active | JYNNEOS |
Non-US COVID-19 Vaccine Manufacturer - WHO Authorized (COVAXIN)
502 | COVID-19 IV Non-US Vaccine (COVAXIN) | Active | COVAXIN (Bharat) COVID-19 Vaccine |
Non-US COVID-19 vaccine manufacturer, WHO Authorized (CONVIDECIA) on 5/19/2022
506 | COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology | Active | CONVIDECIA (CanSino Biologics) COVID-19 Vaccine |
Companies include Emergent Product Development Gaithersburg Inc. and former Emergent BioDefense Operations Lansing and Michigan Biologic Products Institute
318 | Anthrax, post-exposure prophylaxis | Active | CYFENDUS |
24 | Anthrax, pre-exposure prophylaxis, post-exposure prophylaxis | Active | BIOTHRAX |
75 | vaccinia (smallpox) | Active | ACAM2000 |
Emergent Biosolutions acquired PaxVax 8/2021, US Vaccines starting to label under Emergent Travel Health Inc.
174 | cholera, live attenuated | Active | VAXCHORA |
25 | typhoid, oral | Active | Vivotif |
includes SmithKline Beecham and Glaxo Wellcome
801 | AS03 Adjuvant | Inactive | AS03 adjuvant |
20 | DTaP | Active | INFANRIX |
110 | DTaP-Hep B-IPV | Active | PEDIARIX |
130 | DTaP-IPV | Active | KINRIX |
52 | Hep A, adult | Active | HAVRIX-ADULT |
83 | Hep A, ped/adol, 2 dose | Active | HAVRIX-PEDS |
104 | Hep A-Hep B | Active | TWINRIX |
08 | Hep B, adolescent or pediatric | Active | ENGERIX B-PEDS |
43 | Hep B, adult | Active | ENGERIX-B-ADULT |
48 | Hib (PRP-T) | Active | HIBERIX |
118 | HPV, bivalent | Inactive | CERVARIX |
160 | Influenza A monovalent (H5N1), ADJUVANTED-2013 | Inactive | Influenza A monovalent (H5N1), ADJUVANTED-2013 |
150 | influenza, injectable, quadrivalent, preservative free | Active | Fluarix, quadrivalent, preservative free |
140 | Influenza, seasonal, injectable, preservative free | Inactive | FLUARIX |
163 | meningococcal B, OMV | Active | Bexsero |
148 | Meningococcal C/Y-HIB PRP | Inactive | MENHIBRIX |
136 | Meningococcal MCV4O | Active | Menveo |
03 | MMR | Active | Priorix |
176 | Rabies - IM fibroblast culture | Active | RABAVERT |
119 | rotavirus, monovalent | Active | ROTARIX |
303 | RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF | Active | Arexvy |
115 | Tdap | Active | BOOSTRIX |
187 | zoster recombinant | Active | SHINGRIX |
Grifols is a labeler and not a manufacturer.
09 | Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbed | Inactive | Td, adsorbed |
Part of GlaxoSmithKline
160 | Influenza A monovalent (H5N1), ADJUVANTED-2013 | Active | Influenza A (H5N1) -2013 |
158 | influenza, injectable, quadrivalent | Active | Flulaval quadrivalent |
150 | influenza, injectable, quadrivalent, preservative free | Active | Flulaval, quadrivalent, preservative free |
141 | Influenza, seasonal, injectable | Active | FLULAVAL |
140 | Influenza, seasonal, injectable, preservative free | Inactive | Flulaval, preservative free |
Division of Johnson and Johnson, manufacturer of Covid-19 vaccine
212 | COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL | Active | Janssen (J&J) COVID-19 Vaccine |
formerly Massachusetts Public Health Biologic Laboratories
09 | Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbed | Inactive | Td, adsorbed |
09 | Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbed | Active | TDVAX |
Non-US COVID-19 vaccine manufacturer Cofivenz vaccine recognized by ACIP
512 | SARS-COV-2 COVID-19 VLP Non-US Vaccine (Medicago, Covifenz) | Active | Covifenz |
Subsidiary of AstraZeneca
111 | influenza, live, intranasal | Inactive | FLUMIST |
149 | influenza, live, intranasal, quadrivalent | Active | Flumist quadrivalent |
125 | Novel Influenza-H1N1-09, nasal | Inactive | Novel Influenza-H1N1-09, nasal |
19 | BCG | Active | TICE BCG |
204 | Ebola Zaire vaccine, live, recombinant, 1mL dose | Active | ERVEBO (Ebola Zaire Vaccine, Live) |
52 | Hep A, adult | Active | VAQTA-ADULT |
83 | Hep A, ped/adol, 2 dose | Active | VAQTA-PEDS |
08 | Hep B, adolescent or pediatric | Active | RECOMBIVAX-PEDS |
43 | Hep B, adult | Active | RECOMBIVAX-ADULT |
44 | Hep B, dialysis | Active | RECOMBIVAX-DIALYSIS |
49 | Hib (PRP-OMP) | Active | PEDVAXHIB |
51 | Hib-Hep B | Inactive | COMVAX |
62 | HPV, quadrivalent | Inactive | GARDASIL |
165 | HPV9 | Active | Gardasil 9 |
05 | measles | Inactive | ATTENUVAX |
03 | MMR | Active | M-M-R II |
94 | MMRV | Active | PROQUAD |
215 | Pneumococcal conjugate PCV15, polysaccharide CRM197 conjugate, adjuvant, PF | Active | VAXNEUVANCE |
33 | pneumococcal polysaccharide PPV23 | Active | PNEUMOVAX 23 |
116 | rotavirus, pentavalent | Active | ROTATEQ |
06 | rubella | Inactive | MERUVAX II |
21 | varicella | Active | VARIVAX |
121 | zoster live | Active | ZOSTAVAX |
New vaccine manufacturer effective 11/1/2020
US Based - Joint manufacturing partnership, initial vaccine Vaxelis 10/2020
146 | DTaP,IPV,Hib,HepB | Active | VAXELIS |
211 | COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL | Active | Novavax COVID-19 Vaccine (Non-US Tradenames NUVAXOVID, COVOVAX) |
313 | COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5 mcg/0.5 mL | Active | Novavax COVID-19 Vaccine, Adjuvanted (US Only) |
COVID-19 vaccine in co-development with BioNTech. Pfizer includes Wyeth-Lederle Vaccines and Pediatrics, Wyeth Laboratories, Lederle Laboratories, and Praxis Biologics
Acquired by Sanofi Pasteur (08/28/2017), continues to manufacture vaccines distributed by Sanofi
155 | influenza, recombinant, injectable, preservative free | Active | Flublok |
185 | influenza, recombinant, quadrivalent,injectable, preservative free | Inactive | Flublok quadrivalent |
Formerly Aventis Pasteur, Pasteur Merieux Connaught; includes Connaught Laboratories and Pasteur Merieux. Acquired ACAMBIS; Acquired Protein Sciences (8/28/2017)
Seqirus acquired the flu vaccines from Novartis. It also includes the CSL vaccines.
205 | Influenza vaccine, quadrivalent, adjuvanted | Active | FLUAD Quadrivalent |
171 | Influenza, injectable, MDCK, preservative free, quadrivalent | Active | flucelvax, quadrivalent, preservative free |
186 | Influenza, injectable, MDCK, quadrivalent, preservative | Active | Flucelvax, quadrivalent, with preservative |
158 | influenza, injectable, quadrivalent | Active | Afluria, quadrivalent |
150 | influenza, injectable, quadrivalent, preservative free | Active | Afluria quadrivalent preservative free |
161 | Influenza, injectable,quadrivalent, preservative free, pediatric | Active | Afluria quadrivalent, preservative free, pediatric |
141 | Influenza, seasonal, injectable | Active | Afluria |
141 | Influenza, seasonal, injectable | Active | Fluvirin |
140 | Influenza, seasonal, injectable, preservative free | Inactive | Afluria, preservative free |
140 | Influenza, seasonal, injectable, preservative free | Inactive | Fluvirin preservative free |
168 | influenza, trivalent, adjuvanted | Active | Fluad |
Non-US COVID-19 Vaccine Manufacturer - WHO Authorized
510 | COVID-19 IV Non-US Vaccine (BIBP, Sinopharm) | Active | Sinopharm (BIBP) COVID-19 Vaccine |
Non-US COVID-19 Vaccine Manufacturer - WHO Authorized (Sinovac, CoronaVac)
511 | COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac) | Active | Coronavac (Sinovac) COVID-19 Vaccine |
BARR Laboratories merged with TEVA in 2007. The MVX for Barr was retired in 2011, TEVA continues to produce the former BARR vaccines
143 | Adenovirus types 4 and 7 | Active | Adenovirus types 4 and 7 |
Distributes through Intercell in the US
317 | Chikungunya live attenuated vaccine, 0.5 mL, PF | Active | IXCHIQ |
134 | Japanese Encephalitis IM | Active | Ixiaro |
New Vaccine Manufacturer added 1/2022
220 | HepB recombinant, 3-antigen, Al(OH)3 | Active | PREHEVBRIO Hepatitis B Vaccine (Recombinant) |
acquired by Pfizer 10/15/2009
133 | Pneumococcal conjugate PCV 13 | Inactive | PREVNAR 13 |
100 | pneumococcal conjugate PCV 7 | Inactive | PREVNAR 7 |
181 | anthrax immune globulin | Active | n/a |
27 | botulinum antitoxin | Active | n/a |
29 | CMVIG | Active | n/a |
12 | diphtheria antitoxin | Active | n/a |
30 | HBIG | Active | n/a |
86 | IG | Active | n/a |
87 | IGIV | Active | n/a |
157 | Rho(D) -IG IM | Active | n/a |
156 | Rho(D)-IG | Active | n/a |
34 | RIG | Active | n/a |
93 | RSV-MAb | Active | n/a |
196 | Td, adsorbed, preservative free, adult use, Lf unspecified | Active | n/a |
13 | TIG | Active | n/a |
79 | vaccinia immune globulin | Active | n/a |
36 | VZIG | Active | n/a |
Non-US
Inactive
acquired by sanofi in sept 2008
75 | vaccinia (smallpox) | Inactive | ACAM2000 |
Subsidiary of Teva Pharmaceuticals
143 | Adenovirus types 4 and 7 | Inactive | Adenovirus types 4 and 7 |
bioCSL a part of Seqirus
141 | Influenza, seasonal, injectable | Inactive | AFLURIA |
140 | Influenza, seasonal, injectable, preservative free | Inactive | Afluria, preservative free |
127 | Novel influenza-H1N1-09 | Inactive | Novel influenza-H1N1-09 |
126 | Novel influenza-H1N1-09, preservative-free | Inactive | Novel influenza-H1N1-09, preservative-free |
Part of Novartis
18 | rabies, intramuscular injection | Inactive | RabAvert |
acquired Berna, now a J & J company
25 | typhoid, oral | Inactive | VIVOTIF BERNA |
subsidiary of Valneva
134 | Japanese Encephalitis IM | Inactive | IXIARO |
Novartis has sold its flu vaccines to Seqirus and other vaccines to GlaxoSmithKline. While Novartis vaccines may still be in circulation, its status is set to not active.
153 | Influenza, injectable, MDCK, preservative free | Inactive | Flucelvax |
141 | Influenza, seasonal, injectable | Active | FLUVIRIN |
140 | Influenza, seasonal, injectable, preservative free | Inactive | AGRIFLU |
140 | Influenza, seasonal, injectable, preservative free | Inactive | FLUVIRIN-PRESERVATIVE FREE |
168 | influenza, trivalent, adjuvanted | Active | Fluad |
163 | meningococcal B, OMV | Active | Bexsero |
136 | Meningococcal MCV4O | Active | MENVEO |
127 | Novel influenza-H1N1-09 | Inactive | Novel influenza-H1N1-09 |
126 | Novel influenza-H1N1-09, preservative-free | Inactive | Novel influenza-H1N1-09, preservative-free |
176 | Rabies - IM fibroblast culture | Inactive | RABAVERT |
39 | Japanese encephalitis SC | Inactive | JE-VAX |
134 | Japanese Encephalitis IM | Active | IXIARO |
Never Active
57 | hantavirus | Never Active | n/a |
154 | Hep A, IG | Never Active | n/a |
58 | Hep C | Never Active | n/a |
59 | Hep E | Never Active | n/a |
60 | herpes simplex 2 | Never Active | n/a |
61 | HIV | Never Active | n/a |
63 | Junin virus | Never Active | n/a |
64 | leishmaniasis | Never Active | n/a |
65 | leprosy | Never Active | n/a |
67 | malaria | Never Active | n/a |
68 | melanoma | Never Active | n/a |
70 | Q fever | Never Active | n/a |
72 | rheumatic fever | Never Active | n/a |
73 | Rift Valley fever | Never Active | n/a |
145 | RSV-MAb (new) | Never Active | n/a |
117 | VZIG (IND) | Never Active | n/a |
Thank you for choosing Find-A-Code, please Sign In to remove ads.
Printed 2024-05-04 from https://www.findacode.com/cvx/index.html
Copyright © 2000-2024 InnoviHealth Systems Inc - CPT® copyright American Medical Association